BCL2 and breast cancer: We previously demonstrated that inhibition of Bcl-2/Bcl-xL by ABT-737 alone can induce apoptosis in CD34+ CML BC progenitor cells, and this effect is further enhanced by combining ABT-737 with imatinib [14].